Abstract
With the nystatin-perforated whole-cell patch-clamp recording technique, the modulatory effects of adenosine on GABA-activated whole-cell currents were investigated in neurons acutely dissociated from the superficial laminae (laminae I and II) of the rat spinal dorsal horn. The results showed that: (1) GABA acted on GABA(A) receptor and elicited inward Cl(-) currents (I(GABA)) at a holding potential (V(H)) of -40 mV; (2) adenosine suppressed GABA-induced Cl(-) current with affecting neither the reversal potential of I(GABA) nor the apparent affinity of GABA to its receptor; (3) N6-cyclo-hexyladenosine, a selective A(1) adenosine receptor agonist, mimicked the suppressing effect of adenosine on I(GABA), whereas 8-cyclopentyl-1,3-dipropylxanthine, a selective A(1) adenosine receptor antagonist, blocked the suppressing effect of adenosine; (4) chelerythrine, an inhibitor of protein kinase C, reduced the suppressing effect of adenosine on I(GABA); (5) pretreatment with 1,2-bis-(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid tetrakis (acetoxy-methyl) ester, a Ca(2+) chelator, did not affect adenosine-induced suppression of I(GABA). The results indicate that: (1) the suppression of adenosine on I(GABA) is mediated by adenosine A(1) receptor and through a Ca(2+)-independent protein kinase C transduction pathway; (2) the interactions between adenosine and GABA might be involved in the modulation of nociceptive information transmission at spinal cord level.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenosine / agonists
-
Adenosine / analogs & derivatives
-
Adenosine / antagonists & inhibitors
-
Adenosine / pharmacology*
-
Alkaloids
-
Analgesics / pharmacology*
-
Animals
-
Animals, Newborn
-
Benzophenanthridines
-
Bicuculline / pharmacology
-
Chelating Agents / pharmacology
-
Diglycerides / pharmacology
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Egtazic Acid / analogs & derivatives*
-
Egtazic Acid / pharmacology
-
Electric Conductivity
-
Enzyme Inhibitors / pharmacology
-
GABA Agonists / pharmacology
-
GABA Antagonists / pharmacology
-
Isoquinolines / pharmacology
-
Lithium / pharmacology
-
Membrane Potentials / drug effects
-
Muscimol / pharmacology
-
Neural Inhibition / drug effects
-
Patch-Clamp Techniques / methods
-
Phenanthridines / pharmacology
-
Posterior Horn Cells / drug effects*
-
Posterior Horn Cells / physiology
-
Purinergic P1 Receptor Agonists
-
Purinergic P1 Receptor Antagonists
-
Rats
-
Rats, Sprague-Dawley
-
Spinal Cord / cytology
-
Spinal Cord / drug effects
-
Spinal Cord / physiology
-
Sulfonamides*
-
Xanthines / pharmacology
-
gamma-Aminobutyric Acid / pharmacology*
Substances
-
Alkaloids
-
Analgesics
-
Benzophenanthridines
-
Chelating Agents
-
Diglycerides
-
Enzyme Inhibitors
-
GABA Agonists
-
GABA Antagonists
-
Isoquinolines
-
Phenanthridines
-
Purinergic P1 Receptor Agonists
-
Purinergic P1 Receptor Antagonists
-
Sulfonamides
-
Xanthines
-
Muscimol
-
Egtazic Acid
-
gamma-Aminobutyric Acid
-
1-oleoyl-2-acetylglycerol
-
Lithium
-
1,3-dipropyl-8-cyclopentylxanthine
-
chelerythrine
-
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
-
Adenosine
-
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
-
Bicuculline